Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid.

Vethe NT, Ali AM, Reine PA, Andersen AM, Bremer S, Line PD, Rootwelt H, Bergan S.

Ther Drug Monit. 2014 Feb;36(1):108-18. doi: 10.1097/FTD.0b013e3182a13900.

PMID:
24061448
2.

Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals.

Vethe NT, Bremer S, Rootwelt H, Bergan S.

Ther Drug Monit. 2008 Dec;30(6):647-55. doi: 10.1097/FTD.0b013e31818955c3.

PMID:
18806697
4.

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study.

Bremer S, Vethe NT, Rootwelt H, Jørgensen PF, Stenstrøm J, Holdaas H, Midtvedt K, Bergan S.

J Transl Med. 2009 Jul 27;7:64. doi: 10.1186/1479-5876-7-64.

5.

Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.

Reine PA, Vethe NT, Kongsgaard UE, Andersen AM, Line PD, Ali AM, Bergan S.

Scand J Clin Lab Invest. 2013 Mar;73(2):117-24. doi: 10.3109/00365513.2012.745947. Epub 2013 Jan 3.

PMID:
23281843
6.

Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.

Chiarelli LR, Molinaro M, Libetta C, Tinelli C, Cosmai L, Valentini G, Dal Canton A, Regazzi M.

Br J Clin Pharmacol. 2010 Jan;69(1):38-50. doi: 10.1111/j.1365-2125.2009.03542.x.

7.

Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.

Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW.

Transplantation. 1996 Sep 15;62(5):666-72.

PMID:
8830834
8.

Expression of IMPDH1 is regulated in response to mycophenolate concentration.

Bremer S, Vethe NT, Rootwelt H, Bergan S.

Int Immunopharmacol. 2009 Feb;9(2):173-80. doi: 10.1016/j.intimp.2008.10.017. Epub 2008 Nov 20.

PMID:
19010451
9.

IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.

Vethe NT, Bremer S, Bergan S.

Scand J Clin Lab Invest. 2008;68(4):277-85. doi: 10.1080/00365510701724871.

PMID:
18609073
10.

Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.

Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S.

Scand J Clin Lab Invest. 2006;66(1):31-44.

PMID:
16464785
11.

Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.

Rother A, Glander P, Vitt E, Czock D, von Ahsen N, Armstrong VW, Oellerich M, Budde K, Feneberg R, Tönshoff B, Weber LT.

Eur J Clin Pharmacol. 2012 Jun;68(6):913-22. doi: 10.1007/s00228-011-1203-4. Epub 2012 Jan 25.

PMID:
22274404
12.

Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.

Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA.

J Clin Pharmacol. 2011 Mar;51(3):309-20. doi: 10.1177/0091270010368542. Epub 2010 Apr 23.

13.

Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.

Mino Y, Naito T, Otsuka A, Ozono S, Kagawa Y, Kawakami J.

Clin Chim Acta. 2009 Nov;409(1-2):56-61. doi: 10.1016/j.cca.2009.08.016. Epub 2009 Aug 31.

PMID:
19723513
14.

Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.

Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millán O, Carrillo M, Rojo I, Corbella J.

Transpl Int. 2000;13 Suppl 1:S301-5.

15.

Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model.

Langman LJ, Shapiro AM, Lakey JR, LeGatt DF, Kneteman NM, Yatscoff RW.

Transplantation. 1996 Jan 15;61(1):87-92.

PMID:
8560580
16.

Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.

Weimert NA, Derotte M, Alloway RR, Woodle ES, Vinks AA.

Ther Drug Monit. 2007 Apr;29(2):141-9. Review.

PMID:
17417067
17.

High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis.

Schaier M, Scholl C, Scharpf D, Schmitt WH, Schwenger V, Zeier M, Sommerer C.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i138-45. doi: 10.1093/ndt/gfv065.

PMID:
25805745
18.

Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients.

Thi MT, Mourad M, Capron A, Tshinanu FM, Vincent MF, Wallemacq P.

Clin Biochem. 2015 Apr;48(6):401-5. doi: 10.1016/j.clinbiochem.2014.12.005. Epub 2014 Dec 16.

PMID:
25523299
19.

Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression.

Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S.

Transplantation. 2008 Jan 15;85(1):55-61. doi: 10.1097/01.tp.0000296854.68123.03.

PMID:
18192912
20.

Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Bemer MJ, Risler LJ, Phillips BR, Wang J, Storer BE, Sandmaier BM, Duan H, Raccor BS, Boeckh MJ, McCune JS.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1544-52. doi: 10.1016/j.bbmt.2014.05.032. Epub 2014 Jun 9.

Items per page

Supplemental Content

Write to the Help Desk